FrancophonIA/ELRC3.0 huggingface dataset:
English: Management of immune-related adverse reactions may require withholding of a dose or permanent discontinuation of YERVOY therapy and institution of systemic high-dose corticosteroid.
Danish: Behandling af immunrelaterede bivirkninger kan nødvendiggøre udsættelse af en dosis eller permanent seponering af YERVOY og påbegyndelse af behandling med systemisk højdosis kortikosteroid.
English: Thus, the effect of ipilimumab on male and female fertility is unknown.
Danish: Derfor er ipilimumabs virkning på fertiliteten hos hanner og hunner ukendt.
English: Ipilimumab-induced rash and pruritus should be managed based on severity.
Danish: Behandling af ipilimumab-induceret udslæt og pruritus bør være baseret på sværhedsgrad.
English: Adverse reactions reported in patients with advanced melanoma who were treated with ipilimumab 3 mg/kg in clinical trials (n= 767) and from post-marketing surveillance are presented in Table 4.
Danish: De bivirkninger, der er rapporteret hos patienter med fremskredent melanom, som blev behandlet med ipilimumab 3 mg/kg i kliniske forsøg (n= 767), og fra overvågning efter markedsføring, er opstillet i Tabel 4.
English: Signs and symptoms of colitis may include diarrhoea (watery, loose or soft stools), an increased number of bowel movements than usual, blood in your stools or darker-coloured stools, pain or tenderness in your stomach area.
Danish: Tegn og symptomer på colitis kan være diarre (vandig, løs eller blød afføring), flere afføringer end normalt, blod i afføringen eller mørkfarvet afføring, smerter eller ømhed i maveområdet.
English: Each ml of concentrate contains 0.1 mmol sodium, which is 2.30 mg sodium.
Danish: En ml koncentrat indeholder 0,1 mmol natrium, hvilket svarer til 2,30 mg natrium.
English: sodium chloride 9 mg/ml (0.9%) solution for injection; or
Danish: natriumchlorid 9 mg/ml (0,9 %) injektionsvæske; eller
English: In case of a severe or life-threatening infusion reaction, the ipilimumab or ipilimumab in combination with nivolumab infusion must be discontinued and appropriate medical therapy administered.
Danish: I tilfælde af en svær eller livstruende infusionsreaktion skal infusionen med ipilimumab eller ipilimumab i kombination med nivolumab seponeres og passende medicinsk behandling gives.
English: Disease specific precautions
Danish: Sygdomsspecifikke forsigtighedsregler
English: From a microbiological point of view, once opened, the medicine should be infused or diluted and infused immediately.
Danish: Ud fra en mikrobiologisk betragtning bør medicinen infunderes eller fortyndes og infunderes umiddelbart efter åbning.
English: If you miss an appointment, ask your doctor when to schedule your next dose.
Danish: Hvis du glemmer en aftale, skal du spørge lægen om at få en ny aftale.
English: BORR in the 10 mg/kg group was 15.3% (95% CI: 11.8, 19.5) and in the 3 mg/kg group was 12.2% (95% CI: 9.0, 16.0).
Danish: BORR i 10 mg/kg-gruppen var 15,3 % (95 % CI: 11,8; 19,5) og i 3 mg/kg-gruppen var den 12,2 % (95 % CI: 9,0; 16,0).
English: If resolution has not occurred, continue to withhold doses until resolution then resume treatment.d
Danish: Hvis remission ikke er indtrådt, udsættes doserne fortsat indtil remission, hvorefter behandlingen genoptages.
English: Excipients: Tris hydrochloride, sodium chloride, mannitol (E421), pentetic acid, polysorbate 80, sodium hydroxide, hydrochloric acid, water for injections.
Danish: Hjælpestoffer: Tris‑hydrochlorid, natriumchlorid, mannitol (E421), pentetatsyre, polysorbat 80, natriumhydroxid, saltsyre, vand til injektionsvæsker.
English: Ipilimumab alone is used to treat advanced melanoma (a type of skin cancer) in adults and adolescents 12 years of age and older.
Danish: Ipilimumab alene anvendes til behandling af fremskredent melanom (en bestemt type hudkræft) hos voksne og unge på 12 år og derover.
English: Clinical presentation may include diarrhoea, increased frequency of bowel movements, abdominal pain, or haematochezia, with or without fever.
Danish: Den kliniske tilstand kan omfatte diarre, hyppigere afføring, mavesmerter eller hæmatokesi, med eller uden feber.
English: Patients with ocular melanoma, primary CNS melanoma, active brain metastases, human immunodeficiency virus (HIV), hepatitis B, and hepatitis C were not included in the MDX010-20 clinical trial.
Danish: Patienter med okulært melanom, primært CNS‑melanom, aktive hjernemetastaser, human immundefekt virus (HIV), hepatitis B og hepatitis C blev ikke inkluderet i det kliniske forsøg MDX010-20.
English: The YERVOY infusion must not be administered as an intravenous push or bolus injection.
Danish: YERVOY infusionen må ikke administreres som intravenøs bolusinjektion.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of concentrate contains 5 mg ipilimumab.
Danish: KVALITATIV OG KVANTITATIV SAMMENSÆTNING Hver ml koncentrat indeholder 5 mg ipilimumab.
English: Thirty-two patients received re-treatment: 8 in the ipilimumab monotherapy group, 23 in the ipilimumab + gp100 group, and 1 in the gp100 group.
Danish: 32 patienter blev genbehandlet: 8 i ipilimumab monoterapigruppen, 23 i ipilimumab + gp100-gruppen og 1 i gp100-gruppen.
English: Yervoy in combination with nivolumab: When ipilimumab 3 mg/kg was administered in combination with nivolumab 1 mg/kg, there was no effect of nivolumab on the CL of ipilimumab.
Danish: YERVOY i kombination med nivolumab: Når ipilimumab 3 mg/kg blev administreret i kombination med nivolumab 1 mg/kg, var der ingen effekt af nivolumab på ipilimumabs CL.
English: Ipilimumab therapy was discontinued for adverse reactions in 10% of patients.
Danish: Behandlingen med ipilimumab blev seponeret på grund af bivirkninger hos 10 % af patienterne.
English: Figure 1: Overall Survival with ipilimumab 3 mg/kg in pooled analysis
Danish: Figur 1: Samlet overlevelse med ipilimumab 3 mg/kg i puljet analyse
English: In the absence of data, nivolumab should be used with caution in these populations after careful consideration of the potential benefit/risk on an individual basis.
Danish: Da der ikke foreligger data, bør nivolumab anvendes med forsigtighed hos disse populationer og kun efter omhyggelig afvejning af de potentielle fordele/risici for hver enkelt patient.
English: Once symptoms or laboratory abnormalities are controlled and overall patient improvement is evident, treatment with ipilimumab may be resumed and initiation of corticosteroid taper should be based on clinical judgment.
Danish: Når først symptomerne eller de laboratoriemæssige abnormaliteter er under kontrol og en generel bedring hos patienten er tydelig, kan behandlingen med YERVOY genoptages og initiering af nedtrapning af kortikosteroid-dosis bør baseres på en klinisk vurdering.
English: A total of 727 patients were randomized, 362 to receive ipilimumab 3 mg/kg and 365 to receive ipilimumab 10 mg/kg every 3 weeks for 4 doses.
Danish: Totalt 727 patienter blev randomiseret; 362 fik ipilimumab 3 mg/kg og 365 fik ipilimumab 10 mg/kg hver 3. uge til i alt 4 doser.
English: The primary endpoint was OS in the ipilimumab+ gp100 group vs. the gp100 group.
Danish: Det primære endepunkt var OS i ipilimumab+ gp100‑gruppen versus gp100‑gruppen.
English: In patients who received 3 mg/kg ipilimumab monotherapy in MDX010-20, the most frequently reported adverse reactions (≥ 10% of patients) were diarrhoea, rash, pruritus, fatigue, nausea, vomiting, decreased appetite, and abdominal pain.
Danish: Hos patienter, der fik 3 mg/kg ipilimumab monoterapi i MDX010-20, var de hyppigste bivirkninger (≥ 10 % af patienterne) diarre, udslæt, pruritus, træthed, kvalme, opkastning, nedsat appetit og mavesmerter.
English: Management of these adverse reactions may also require systemic high-dose corticosteroid therapy if demonstrated or suspected to be immune-related (see section 4.4 for detailed management guidelines).
Danish: Håndtering af sådanne bivirkninger kan også kræve behandling med systemisk højdosis kortikosteroid, hvis det er vist eller ved mistanke om, at de er immunrelaterede (se pkt.
English: However, systemic corticosteroids or other immunosuppressants can be used after starting ipilimumab to treat immune-related adverse reactions.
Danish: Systemiske kortikosteroider eller andre immunosuppressiva kan imidlertid anvendes til behandling af immunrelaterede bivirkninger efter initiering af ipilimumab.
English: Immune-related colitis Ipilimumab in combination with nivolumab
Danish: Immunrelateret colitis Ipilimumab i kombination med nivolumab
English: Skin:
Danish: Hud:
English: loosening of membrane at the back of the eye (serous retinal detachment)
Danish: løsning af hinde bagerst i øjet (serøs nethindeløsning)
English: Before initiating treatment with ipilimumab monotherapy in adolescents of 12 years and older, physicians are advised to carefully evaluate the individual patient, taking into consideration the limited available data, the observed benefits and the toxicity of ipilimumab monotherapy in the paediatric population (see sections 4.8 and 5.1).
Danish: Før ipilimumab monoterapi påbegyndes hos unge på 12 år og derover, anbefales det, at læger nøje evaluerer den individuelle patient og tager højde for den begrænsede mængde tilgængelige data, de observerede gunstige virkninger og toksiciteten af ipilimumab monoterapi i den pædiatriske population (se pkt.
English: Of patients 12 years of age and older with advanced melanoma, ipilimumab 5 mg/kg was administered to three patients and ipilimumab 10 mg/kg was administered to two patients.
Danish: Hos patienter på 12 år eller derover med fremskredent melanom, blev ipilimumab 5 mg/kg administreret til 3 patienter og ipilimumab 10 mg/kg administreret til 2 patienter.
English: Signs and symptoms of severe skin reaction may include such as skin rash with or without itching, peeling of the skin, dry skin, fever, fatigue, swelling of the face or lymph glands, increase of eosinophils (type of white blood cells) and effects on liver, kidneys or lungs.
Danish: Tegn og symptomer på en alvorlig hudreaktion kan være hududslæt med eller uden kløe, afskalning af huden, tør hud, feber, træthed, hævelse af ansigt eller lymfekirtler, øget mængde eosinofile celler (bestemt type hvide blodlegemer) og påvirkning af lever, nyrer eller lunger.
English: * ipilimumab in combination with nivolumab for the first 4 doses then followed by nivolumab monotherapy in melanoma.
Danish: * ipilimumab i kombination med nivolumab for de første 4 doser, derefter efterfulgt af nivolumab som monoterapi ved melanom.
English: - Problems with your lungs such as breathing difficulties or cough.
Danish: - problemer med lungerne, f.eks.vejrtrækningsbesvær eller hoste.
English: Median OS for tumour PD-L1 expression ≥ 1% was not reached for ipilimumab in combination with nivolumab, and was 19.61 months in the sunitinib arm (HR = 0.52; 95% CI: 0.34, 0.78).
Danish: Median OS for PD-L1tumorekspression ≥ 1 % blev ikke nået for ipilimumab i kombination med nivolumab, og var 19,61 måneder i sunitinib-armen (HR = 0,52; 95 % CI: 0,34; 0,78).
English: Use a separate infusion line for the infusion.
Danish: Der skal anvendes en separat infusionsslange.
English: - - -*- - - - Nivolumab+ipilimumab (events: 161/314), median and 95% CI: 11.50 (8.90, 22.18).
Danish: - - -*- - - - Nivolumab+ipilimumab (hændelser: 161/314), median og 95 % CI: 11,50 (8,90; 22,18).
English: Detailed guidelines for the management of immune-related adverse reactions are described in section 4.4.
Danish: Detaljerede retningslinjer for behandling af immunrelaterede bivirkninger er beskrevet i pkt.
English: When administered in combination with nivolumab, the CL of ipilimumab increased by 5.7% in the presence of anti-ipilimumab antibodies and the CL of nivolumab increased by 20% in the presence of presence of anti-nivolumab antibodies.
Danish: Når ipilimumab blev administreret i kombination med nivolumab øgedes ipilimumabs CL med 5,7 % ved tilstedeværelse af anti-ipilimumab-antistoffer og nivolumabs CL øgedes med 20 % ved tilstedeværelse af anti-nivolumab-antistoffer.
English: Randomised phase 2 study of ipilimumab in combination with nivolumab and ipilimumab (CA209069)
Danish: Randomiseret fase 2-studie med ipilimumab i kombination med nivolumab og ipilimumab (CA209069)
English: Patients may present with muscle weakness.
Danish: Patienter kan udvikle nedsat muskelkraft.
English: Patients with a baseline performance score ≥ 2, active brain metastases or autoimmune disease, and patients who had been receiving systemic immunosuppressants prior to study entry were excluded from the clinical trials of ipilimumab in combination with nivolumab.
Danish: Patienter med en performance-score ved baseline ≥ 2, aktive hjernemetastaser eller autoimmun sygdom og patienter, som havde fået systemiske immunsuppressiva før studieinklusion, blev ikke inkluderet i de kliniske forsøg med ipilimumab i kombination med nivolumab.
English: Before initiating treatment with the combination, physicians are advised to carefully evaluate the individual patient and tumour characteristics, taking into consideration the observed benefits and the toxicity of the combination relative to nivolumab monotherapy (see sections 4.8 and 5.1).
Danish: Før behandling med kombinationen indledes, bør lægen omhyggeligt vurdere den enkelte patient og tumorkarakteristika, samtidig med at observerede fordele og toksicitet ved kombinationen i forhold til nivolumab-monoterapi tages i betragtning (se pkt.
English: However, because of the potential for adverse reactions in nursing infants, a decision must be made whether to discontinue breast-feeding or to discontinue from YERVOY therapy taking into account the benefit of breast-feeding for the child and the benefit of YERVOY therapy for the woman.
Danish: På grund af risikoen for bivirkninger hos ammede spædbørn skal det under hensyntagen til fordelen for barnet ved amning og fordelen for kvinden ved behandling med YERVOY afgøres, hvorvidt amningen eller behandlingen med YERVOY skal afbrydes.
English: Each 10 ml vial of YERVOY concentrate provides 50 mg of ipilimumab; each 40 ml vial provides 200 mg of ipilimumab.
Danish: Et 10 ml hætteglas med YERVOY koncentrat giver 50 mg ipilimumab; et 40 ml hætteglas giver 200 mg ipilimumab.
English: The safety and efficacy of ipilimumab in children younger than 12 years of age has not been established.
Danish: Ipilimumabs sikkerhed og virkning hos børn under 12 år er ikke klarlagt.
English: Ipilimumab-induced rash and pruritus were predominantly mild or moderate (Grade 1 or 2) and responsive to symptomatic therapy.
Danish: Ipilimumab-induceret udslæt og pruritus var hovedsageligt let eller moderat (Grad 1 eller 2) og responderede på symptomatisk behandling.
English: For tumour PD-L1 expression < 1%, the median OS was 34.7 months for the ipilimumab in combination with nivolumab and was 32.2 months in the sunitinib arm (HR = 0.70; 95% CI: 0.54, 0.92).
Danish: For PD-L1-tumorekspression < 1 % var median OS 34,7 måneder for ipilimumab i kombination med nivolumab, og den var 32,2 måneder for sunitinib-armen (HR = 0,70; 95 % CI: 0,54; 0,92).
English: Ipilimumab in combination with nivolumab must be permanently discontinued for any severe immune-related adverse reaction that recurs and for any life-threatening immune-related adverse reaction.
Danish: Ipilimumab i kombination med nivolumab skal seponeres permanent i tilfælde af enhver recidiverende alvorlig immunrelateret bivirkning og enhver livstruende immunrelateret bivirkning.
English: In most reported cases prior or concurrent therapy with a PD-1 or PD-L1 inhibitor has occurred.
Danish: I de fleste rapporterede tilfælde har der været tidligere eller samtidig behandling med PD-1- eller PD-L1-hæmmere.
English: The overall safety profile of ipilimumab 3 mg/kg in clinical trial CA184-169 (N=362) was consistent with that established for ipilimumb in patients treated for advanced melanoma.
Danish: Samlet set var sikkerhedsprofilen for ipilimumab 3 mg/kg i det kliniske forsøg CA184-169 (N=362) i overensstemmelse med den, der er konstateret for ipilimumab hos patienter i behandling for fremskredent melanom.
English: The recommended induction regimen of YERVOY is 3 mg/kg administered intravenously over a 90-minute period every 3 weeks for a total of 4 doses.
Danish: Den anbefalede induktionsbehandling med YERVOY er 3 mg/kg administreret intravenøst over en periode på 90 minutter hver 3. uge til i alt 4 doser.
English: You must use effective contraception while you are being treated with YERVOY if you are a woman who could become pregnant.
Danish: Du skal anvende sikker prævention, mens du behandles med YERVOY, hvis du er en kvinde i den fødedygtige alder. Fortæl det til lægen, hvis du bliver gravid, mens du anvender YERVOY.
English: Liver biopsies from patients who had immune-related hepatotoxicity showed evidence of acute inflammation (neutrophils, lymphocytes, and macrophages).
Danish: Leverbiopsier fra patienter, som havde immunrelateret levertoksicitet, viste tegn på akut inflammation (neutrofile granulocytter, lymfocytter og makrofager).
English: Of patients evaluable for the presence of anti-nivolumab antibodies, the incidence of anti-nivolumab antibodies was 26% with nivolumab 3 mg/kg and ipilimumab 1 mg/kg every 3 weeks and 37.8% with nivolumab 1 mg/kg and ipilimumab 3 mg/kg every 3 weeks.
Danish: Af de patienter, som var evaluerbare for tilstedeværelse af anti-nivolumab-antistoffer, var forekomsten af anti-nivolumab-antistoffer 26 % med nivolumab 3 mg/kg og ipilimumab 1 mg/kg hver 3. uge og 37,8 % med nivolumab 1 mg/kg og ipilimumab 3 mg/kg hver 3. uge.
English: In the absence of data, ipilimumab in combination with nivolumab should be used with caution in these populations after careful consideration of the potential benefit/risk on an individual basis.
Danish: Da der ikke foreligger data, bør ipilimumab i kombination med nivolumab anvendes med forsigtighed hos disse populationer og kun efter omhyggelig afvejning af de potentielle fordele/risici for hver enkelt patient.
English: Immune-related endocrinopathy observed in clinical trials was generally controlled with immunosuppressive therapy and hormone replacement therapy.
Danish: Immunrelateret endokrinopati, der blev observeret i kliniske forsøg, blev generelt behandlet med immunsuppresiv behandling og hormonsubstitutionsbehandling.
English: The safety and efficacy of ipilimumab 1 mg/kg in combination with nivolumab 3 mg/kg for the treatment of advanced/metastatic RCC was evaluated in a phase 3, randomised, open-label study (CA209214).
Danish: Sikkerheden og virkningen af ipilimumab 1 mg/kg i kombination med nivolumab 3 mg/kg til behandling af fremskredent/metastatisk RCC blev undersøgt i et randomiseret, åbent fase 3 studie (CA209214).
English: Time to onset of moderate to very severe (Grade 2 to 4) immune-related endocrinopathy ranged from 7 to nearly 20 weeks from the start of treatment.
Danish: Moderat til meget svær (Grad 2-4) immunrelateret endokrinopati indtrådte fra 7 til næsten 20 uger efter behandlingsstart.
English: Adverse reactions reported in the pooled dataset for patients treated with ipilimumab 3 mg/kg in combination with nivolumab 1 mg/kg (n = 448) are presented in Table 5.
Danish: Bivirkninger, der blev rapporteret i det puljede datasæt for patienter behandlet med ipilimumab 3 mg/kg i kombination med nivolumab 1 mg/kg (n = 448), er vist i Tabel 5.
English: YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).
Danish: YERVOY i kombination med nivolumab er indiceret til førstelinjebehandling af voksne patienter med fremskredent renalcellekarcinom i mellem- eller højrisikogruppen (se pkt.
English: The following immune-related adverse reactions were reported in less than 1% of patients treated with ipilimumab in combination with nivolumab in clinical trials across doses and tumour types: pancreatitis, uveitis, demyelination, autoimmune neuropathy (including facial and abducens nerve paresis), Guillain-Barré syndrome, myasthenia gravis, myasthenic syndrome, aseptic meningitis, encephalitis, gastritis, sarcoidosis, duodenitis, myositis, myocarditis, and rhabdomyolysis.
Danish: I kliniske studier blev der på tværs af doser og tumortyper rapporteret følgende immunrelaterede bivirkninger hos færre end 1 % af de patienter, der blev behandlet med ipilimumab i kombination med nivolumab: pancreatitis, uveitis, demyelinisering, autoimmun neuropati (herunder facial og nervus abducens parese), Guillain-Barré syndrom, myasthenia gravis, myastenisk syndrom, aseptisk meningitis, encephalitis, gastritis, sarkoidose, duodenitis, myositis, myokarditis og rhabdomyolyse.
English: If initial symptoms improve to mild (Grade 1) or resolve, ipilimumab therapy may be resumed (see section 4.2).
Danish: Hvis de første symptomer bedres til let (Grad 1) eller ophører, kan behandling med ipilimumab genoptages (se pkt.
English: Uncommon spondyloarthropathy, Sjogren's syndrome, arthritis, myopathy, myositis (including polymyositis)a,e, rhabdomyolysisa,f polymyalgia rheumatica, myositis (including polymyositis), rhabdomyolysis
Danish: Ikke almindelig spondylartropati, Sjögrens syndrom, artritis, myopati, myositis (herunder polymyositis)a,e, rhabdomyolysea,f polymyalgia rheumatica, myositis (inklusive polymyositis), rabdomyolyse
English: Time (months)
Danish: Måneder (interval)
English: In a Phase 1 trial, asymptomatic grade 3 increases in transaminases (ALT/AST > 5 × ULN) and bilirubin (total bilirubin > 3 × ULN) were reported with concurrent administration of ipilimumab (3 mg/kg) and vemurafenib (960 mg BID or 720 mg BID).
Danish: Ved et fase 1-studie blev der rapporteret om asymptomatiske Grad 3-stigninger i aminotransferaser (ALAT/ASAT > 5 × ULN) og bilirubin (total-bilirubin > 3 × ULN) ved samtidig administration af ipilimumab (3 mg/kg) og vemurafenib (960 mg to gange dagligt eller 720 mg to gange dagligt).
English: Signs and symptoms may include redness in the eye, pain in the eye, vision problems, blurry vision or temporary loss of sight.
Danish: Tegn og symptomer kan være røde øjne, smerter i øjnene, synsproblemer, sløret syn eller midlertidigt synstab.
English: Ipilimumab in combination with nivolumab should be discontinued for life-threatening or recurrent severe cardiac and pulmonary adverse reactions (see section 4.2).
Danish: Ipilimumab i kombination med nivolumab bør seponeres ved livstruende eller tilbagevendende alvorlige kardielle og pulmonale bivirkninger (se pkt.
English: Ipilimumab in combination with nivolumab must be permanently discontinued for life-threatening diabetes.
Danish: Ipilimumab i kombination with nivolumab skal seponeres permanent i tilfælde af livstruende diabetes.
English: Ipilimumab in combination with nivolumab is associated with immune-related adverse reactions.
Danish: Ipilimumab i kombination med nivolumab er associeret med immunrelaterede bivirkninger.
English: A total of 1096 patients were randomised in the trial, of which 847 patients had intermediate/poor-risk RCC and received either ipilimumab 1 mg/kg (n = 425) administered intravenously over 30 minutes in combination with nivolumab administered intravenously over 60 minutes every 3 weeks for 4 doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks or sunitinib (n = 422) 50 mg daily, administered orally for 4 weeks followed by 2 weeks off, every cycle.
Danish: Af dem havde 847 patienter mellem- eller højrisikoRCC, og fik enten ipilimumab 1 mg/kg (n = 425) administreret intravenøst over 30 minutter i kombination med nivolumab administreret intravenøst over 60 minutter hver 3. uge for 4 doser, efterfulgt af nivolumab-monoterapi 3 mg/kg hver 2. uge eller sunitinib (n = 422) 50 mg dagligt, administreret oralt i 4 uger efterfulgt af 2 ugers pause, hver cyklus.
English: Randomised phase 3 study of ipilimumab in combination with nivolumab vs. sunitinib (CA209214)
Danish: Randomiseret fase 3-studie med ipilimumab i kombination med nivolumab versus sunitinib (CA209214)
English: Liver function tests (LFTs) and thyroid function tests should be evaluated at baseline and before each dose of YERVOY.
Danish: Kontrol af levertal og thyreoideafunktionen skal vurderes inden behandlingsstart og inden hver YERVOY-dosis.